The trial data show that the CANNASEN®CBD Arthritis Gel (NGA-01) was well tolerated, and no adverse events/effects have been seen nor reported by the participants.

The primary objective of the clinical trial was to evaluate the efficacy of NGA-01 (CANNASEN®CBD Arthritis Gel) in the relief of joint pain, inflammation and mobility for patients with Arthritis.

The conclusion of the study is as follows; the WOMAC Index and VAS score has significantly reduced in the NGA-01 arm (CANNASEN®CBD Arthritis Gel). All the major attributes like pain, swelling, stiffness, tenderness, crepitus, and pain during flexion have shown improvement during the treatment. Both Subject’s and Physician’s Global Assessments have shown a reduction in the disease intensity on one hand, and EQ-5D has shown betterment in the overall life quality of the subjects. The Treatment was found well tolerable, and no adverse events were reported during the study. The Pain indices, assessments, and life quality questionnaires together confirm that NGA-01 (CANNASEN®CBD Arthritis Gel) is effective in the treatment of osteoarthritis with joint pain, along with improving the overall quality of life.
 

The full study with the results of each primary efficacy endpoint will be published, in a scientific paper developed with the help from The University of Naples Federico II [i]. The scientific paper will be published at a later stage, expectedly within this calendar year.

CEO Lone Henriksen comments:
“The clinical study results mark an important step for CS MEDICA as we continue our strong track record for delivering impactful products. We are proud to share these results as the trial shows that the CANNASEN®CBD Arthritis Gel is proving to be both safe and efficient for patients and most important our CANNASEN®CBD Arthritis Gel improves the overall quality of life for patients with osteoarthritis.”

The study design was a multicentre, randomized, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of NGA-01 (CANNASEN®CBD Arthritis Gel). The patients were administered for up to 60 days and consisted of adults between the ages of 30 to 80 years who have a clinical diagnosis of osteoarthritis with joint pain at any of the following joints: knee, hip, ankle, elbow and shoulder.

All enrolled subjects have received either NGA-01 (CANNASEN®CBD Arthritis Gel) or placebo (randomized in a 1:1 ratio) with the first dose applied at the Day 1 Study Visit. Subjects were instructed to apply the study medication twice daily for 60 days. Subjects visited for study-related assessments on days 1st, 15th, 30th, 45th and 60th day.
 

This disclosure contains information that CS MEDICA A/S is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 23-06-2022 08:00 CET.

For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@galaxapharma.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish medico cannabis company founded in 2011. CS MEDICA is committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids. The Company runs its business through the two fully-owned subsidiaries, Galaxa Pharma A/S (distributor and representative of foreign manufacturers in the Nordic, registered medical device product distributor) and CanNordic A/S (Medical device developer and seller (BtB), registered medical device product manufacturer). CS MEDICA distributes products across the European borders and is headquartered in Copenhagen, Denmark.

The company is listed on Spotlight Stock Market in Stockholm (symbol: "CSMED"). For more information about CS MEDICA cs-medica.com.